Biocartis Enters Commercial Mode with Launch of Platform, $45M Series D Financing Round | GenomeWeb

NEW YORK (GenomeWeb News) – Five years after its founding, Swiss molecular diagnostics firm Biocartis has transitioned to full commercial mode with the launch of its DMAT platform last week and the completion announced today of its Series D financing round bringing in €34.5 million ($45.0 million).

The financing will go toward the launch of the platform as well as validation of its molecular diagnostics platform called Apollo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.